COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Clinical Study Evaluating the Effects of First-line Oral cOmbination theraPy of maciTentan and tadalafIl in Patients With Newly Diagnosed pulMonary Arterial Hypertension (OPTIMA) (OPTIMA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02968901
Recruitment Status : Terminated
First Posted : November 21, 2016
Last Update Posted : October 8, 2019
Information provided by (Responsible Party):

No Study Results Posted on for this Study
Recruitment Status : Terminated
Actual Primary Completion Date : September 10, 2018
Actual Study Completion Date : September 10, 2018